ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för eribulin mesylate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

24 träffar

Bibliografisk träff 2013-02-01

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1365-2125.2012.04381.x

Bibliografisk träff 2012-09-26

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JH.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-012-1976-x

Bibliografisk träff 2012-08-16

A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate.

Nieder C, Aandahl G, Dalhaug A.

Case Rep Oncol Med · research-article; journal article · DOI 10.1155/2012/537183

Bibliografisk träff 2012-07-24

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-11-3075

Bibliografisk träff 2012-06-25

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.

Scarpace SL.

Clin Ther · review; journal article · DOI 10.1016/j.clinthera.2012.06.003

Bibliografisk träff 2012-06-14

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

O'Sullivan Coyne G, Walsh J, Kelly CM.

Expert Opin Drug Saf · journal article · DOI 10.1517/14740338.2012.698608

Bibliografisk träff 2012-05-22

Eribulin: a novel cytotoxic chemotherapy agent.

Preston JN, Trivedi MV.

Ann Pharmacother · review; journal article · DOI 10.1345/aph.1q636

Bibliografisk träff 2012-05-05

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.

Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JH.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s10637-012-9829-3

Bibliografisk träff 2012-05-01

Anticancer drug discovery from the marine environment.

Nastrucci C, Cesario A, Russo P.

Recent Pat Anticancer Drug Discov · review; journal article · DOI 10.2174/157489212799972963

Bibliografisk träff 2012-05-01

Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.

McBride A, Butler SK.

Am J Health Syst Pharm · review; journal article · DOI 10.2146/ajhp110237

Bibliografisk träff 2012-05-01

Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.

Towle MJ, Nomoto K, Asano M, Kishi Y, Yu MJ, Littlefield BA.

Anticancer Res · research support, non-u.s. gov't; journal article

Bibliografisk träff 2012-04-01

Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.

Ayoub JP, Verma Sh, Verma S.

Curr Oncol · research-article; journal article · DOI 10.3747/co.19.1024

Bibliografisk träff 2012-03-01

A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.

Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR.

J Thorac Oncol · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1097/jto.0b013e31823f43ca

Bibliografisk träff 2012-01-26

Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.

Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, Zhao H, Marathe A, Kotch L, Jee J, Wang Y, Zhou L, Adams WM, Jarral V, Pilaro A, Lostritto R, Gootenberg JE, Keegan P, Pazdur R.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-11-2149

Bibliografisk träff 2012-01-01

Eribulin mesylate in the treatment of metastatic breast cancer.

Jain S, Cigler T.

Biologics · review-article; journal article · DOI 10.2147/btt.s19811

Bibliografisk träff 2011-11-14

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.

Muñoz-Couselo E, Pérez-García J, Cortés J.

Onco Targets Ther · review-article; journal article · DOI 10.2147/ott.s16392

Bibliografisk träff 2011-10-11

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.

Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S.

Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1093/annonc/mdr444

Bibliografisk träff 2011-09-20

Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.

Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S.

Cancer · research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1002/cncr.26569

Bibliografisk träff 2011-09-08

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Spira AI, Iannotti NO, Savin MA, Neubauer M, Gabrail NY, Yanagihara RH, Zang EA, Cole PE, Shuster D, Das A.

Clin Lung Cancer · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.cllc.2011.06.010

Bibliografisk träff 2011-09-07

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP.

Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1093/annonc/mdr380

Bibliografisk träff 2011-09-02

Eribulin mesylate in patients with refractory cancers: a Phase I study.

Mukohara T, Nagai S, Mukai H, Namiki M, Minami H.

Invest New Drugs · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-011-9741-2

Bibliografisk träff 2011-05-08

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Cortes J, Montero AJ, Glück S.

Cancer Treat Rev · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.ctrv.2011.03.006

Bibliografisk träff 2011-04-28

A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.

Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, Hedley D, Wang L, Doyle L, Moore MJ.

Invest New Drugs · clinical trial, phase ii; journal article · DOI 10.1007/s10637-011-9673-x

Bibliografisk träff 2011-03-07

Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.

Cortes J, Lorca R.

Future Oncol · journal article · DOI 10.2217/fon.10.186